Table 3. Multivariate Cox regression of the a) clinical parameters and b) clinical and glycan parameters.
| Clinical algorithm | All-cause mortality | Clinical algorithm | CRC mortality | ||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age | 1.03 (1.01–1.04) | 9.2 × 10−6 | Age | 1.02 (1.00–1.03) | 0.02 |
| Sex | 0.91 (0.74–1.12) | 0.36 | Sex | 1.03 (0.82–1.29) | 0.82 |
| AJCC stage 2 vs 1 | 1.30 (0.92–1.83) | 0.14 | AJCC stage 2 vs 1 | 2.22 (1.33–3.72) | 0.002 |
| AJCC stage 3 vs 1 | 2.44 (1.77–3.38) | 7.3 × 10−8 | AJCC stage 3 vs 1 | 5.02 (3.09–8.15) | 6.7 × 10−11 |
| AJCC stage 4 vs 1 | 15.92 (11.16–22.70) | <2.0 × 10−16 | AJCC stage 4 vs 1 | 34.05 (20.60–56.29) | <2.0 × 10−16 |
| CRP | 1.96 (1.47–2.62) | 4.9 × 10−6 | CRP | 2.08 (1.52–2.86) | 4.8 × 10−6 |
| BMI | 1.04 (1.01–1.06) | 0.002 | BMI | 1.05 (1.02–1.08) | 0.0001 |
| Harrell’s C | 0.73 | Harrell’s C | 0.77 | ||
| IDIa | 0.02 | IDIa | 0.04 | ||
| AUC | 0.74 | AUC | 0.79 | ||
| Clinical/glycans algorithm | All-cause mortality | Clinical/glycans algorithm | CRC mortality | ||
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age | 1.02 (1.01–1.03) | 0.003 | Age | 1.01 (0.99–1.02) | 0.28 |
| Sex | 0.91 (0.74–1.12) | 0.36 | Sex | 1.04 (0.82–1.30) | 0.77 |
| AJCC stage 2 vs 1 | 1.33 (0.94–1.88) | 0.11 | AJCC stage 2 vs 1 | 2.24 (1.34–3.74) | 0.002 |
| AJCC stage 3 vs 1 | 2.49 (1.80–3.45) | 4.1 × 10−8 | AJCC stage 3 vs 1 | 5.01 (3.09–8.14) | 7.1 × 10−11 |
| AJCC stage 4 vs 1 | 15.72 (10.99–22.49) | <2.0 × 10−16 | AJCC stage 4 vs 1 | 33.63 (20.18–56.04) | <2.0 × 10−16 |
| CRP | 1.66 (1.23–2.25) | 0.001 | CRP | 1.84 (1.31–2.59) | 0.0004 |
| BMI | 1.03 (1.01–1.06) | 0.006 | BMI | 1.05 (1.02–1.07) | 0.0007 |
| IGP48 | 1.69 (0.64–4.47) | 0.29 | IGP29 | 0.92 (0.81–1.05) | 0.21 |
| IGP26 | 0.72 (0.55–0.95) | 0.02 | IGP13 | 0.85 (0.74–0.97) | 0.01 |
| IGP8 | 0.53 (0.21–1.30) | 0.16 | IGP8 | 0.91 (0.81–1.03) | 0.14 |
| Harrell’s C | 0.73 | Harrell’s C | 0.77 | ||
| IDIb | 0.05 | IDIb | 0.03 | ||
| AUC | 0.75 | AUC | 0.79 | ||
aThe IDI was calculated based on the comparison of model II (adjusted for stage, sex and age) and the full clinical model III (adjusted for stage, age, sex, bmi and CRP – presented here).
bThe IDI was calculated based on the comparison of the full clinical model III (adjusted for stage, age, sex, bmi and CRP) and the full clinical model III with the three top selected glycans.